These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
762 related articles for article (PubMed ID: 26576619)
21. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy. Schaefer JA; Gales MA Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290 [TBL] [Abstract][Full Text] [Related]
22. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study. Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241 [TBL] [Abstract][Full Text] [Related]
23. Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia. Meyer I ANNA J; 1993 Feb; 20(1):93-5. PubMed ID: 8431031 [TBL] [Abstract][Full Text] [Related]
24. Sodium polystyrene sulfonate resin candy for control of potassium in chronic dialysis patients. Johnson K; Cazee C; Gutch C; Ogden D Clin Nephrol; 1976 Jun; 5(6):266-8. PubMed ID: 1277599 [TBL] [Abstract][Full Text] [Related]
25. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218 [TBL] [Abstract][Full Text] [Related]
26. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia--changes in serum potassium levels with or without a RAAS inhibitor. Tomino Y; Yamazaki T; Shou I; Tsuge T; Satake K; Takeda Y; Ohtani A; Nishitani T; Kurusu A; Hamada C; Horikoshi S; Maeda K; Tanaka Y; Fukuda H; Wakabayashi M; Seto T Clin Nephrol; 2007 Dec; 68(6):379-85. PubMed ID: 18184520 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Appropriate Sodium Polystyrene Sulfonate Use With a Hyperkalemia Order Set: A Pilot Study. Mueller ZT; Crannage AJ J Pharm Pract; 2019 Oct; 32(5):493-498. PubMed ID: 29642732 [TBL] [Abstract][Full Text] [Related]
28. Polysulfonate Resins in Hyperkalemia: A Systematic Review. Wong SWS; Zhang G; Norman P; Welihinda H; Wijeratne DT Can J Kidney Health Dis; 2020; 7():2054358120965838. PubMed ID: 33240515 [TBL] [Abstract][Full Text] [Related]
29. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. Noel JA; Bota SE; Petrcich W; Garg AX; Carrero JJ; Harel Z; Tangri N; Clark EG; Komenda P; Sood MM JAMA Intern Med; 2019 Aug; 179(8):1025-1033. PubMed ID: 31180477 [TBL] [Abstract][Full Text] [Related]
30. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia. Linder KE; Krawczynski MA; Laskey D Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581 [TBL] [Abstract][Full Text] [Related]
31. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Chernin G; Gal-Oz A; Ben-Assa E; Schwartz IF; Weinstein T; Schwartz D; Silverberg DS Clin Cardiol; 2012 Jan; 35(1):32-6. PubMed ID: 22057933 [TBL] [Abstract][Full Text] [Related]
32. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of hyperkalemia associated with renal insufficiency--clinical effects and side reactions of positive-ion-exchange resins, sodium polystyrene sulfonate (Kayexalate)]. Takasu T Nihon Rinsho; 1970 Jul; 28(7):1941-6. PubMed ID: 5466528 [No Abstract] [Full Text] [Related]
34. New drugs to prevent and treat hyperkalemia. Lepage L; Desforges K; Lafrance JP Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3-5 non-dialysis chronic kidney disease: a single-center randomized controlled trial. Wang X; Chen D; Song X; Wang J; Zhang H J Int Med Res; 2023 Apr; 51(4):3000605231167516. PubMed ID: 37063062 [TBL] [Abstract][Full Text] [Related]
36. Management of hyperkalemia in hospitalized patients. Fordjour KN; Walton T; Doran JJ Am J Med Sci; 2014 Feb; 347(2):93-100. PubMed ID: 23255245 [TBL] [Abstract][Full Text] [Related]
37. Hyperkalemia in chronic kidney disease. Watanabe R Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s31-s36. PubMed ID: 31939533 [TBL] [Abstract][Full Text] [Related]